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Does South Africa need a national clinical trials support 
unit?
N Siegfried, J Volmink, A Dhansay
The randomised controlled trial (RCT) is the gold standard for 
evaluating the effects of health care interventions.1 Therefore, 
South African health policy and clinical guidelines should 
be based on well-conducted RCTs that ideally are conducted 
within the country to ensure local applicability.
Conducting RCTs in South Africa faces numerous obstacles. 
Specialist training in the universities traditionally focuses on 
clinical experience and skills accrual, and lacks a research 
focus. Downscaled tertiary service units struggle to remain 
academically active,2 reducing the opportunities for local 
clinicians to acquire the epidemiological and statistical skills 
for conducting RCTs. Health professionals interested in 
clinical research may have to migrate to develop these skills. 
Opportunities to then practise those skills may only exist 
overseas, contributing to the professional brain drain.3
When research funding is not available from local sources, 
researchers become dependent on funds from donor agencies 
or the drug industry, potentially deflecting priorities away 
from local needs.4 African governments have committed to 
spend 2% of their health budgets on research.5 In 2008/2009, 
the South African Medical Research Council (MRC) received 
far short of the promised 2% from the national Department of 
Health (DoH), even if National Research Foundation monies 
are added to this.6 The MRC is reported to be chronically 
underfunded despite its mandate to maintain and develop 
clinical research capacity.2
RCTs require intensive planning, co-ordination, expertise7 
and sufficient funding. There is no national institution 
providing a coherent suite of support, available skills and 
training for clinicians wishing to conduct trials in the public 
sector. In many countries, clinical trials support units offer such 
support to clinicians and researchers in a variety of settings.8 
The MRC consequently funded a feasibility study to assess 
the need for establishing a national South African Clinical 
Trials Support Unit. We report on a component of the study 
comprising key informant interviews of national decision-
makers.
Objectives
Our objective was to determine the need for additional 
training and support for conducting randomised clinical trials 
within South African institutions; identify challenges facing 
institutions conducting randomised clinical trials; and provide 




The study was qualitative, comprising key informant 
interviews. Sampling was purposive: the research team 
identified senior decision-makers at stakeholder institutions; 
during their interviews, participants were asked to suggest 
additional key informants to provide contributory insights 
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Background. No national South African institution provides 
a coherent suite of support, available skills and training for 
clinicians wishing to conduct randomised controlled trials 
(RCTs) in the public sector. We report on a study to assess the 
need for establishing a national South African Clinical Trials 
Support Unit.
Objectives. To determine the need for additional training and 
support for conduct of RCTs within South African institutions; 
identify challenges facing institutions conducting RCTs; and 
provide recommendations for enhancing trial conduct within 
South African public institutions.
Design. Key informant interviews of senior decision-makers 
at institutions with a stake in the South African public sector 
clinical trials research environment.
Results. Trial conduct in South Africa faces many challenges, 
including lack of dedicated funding, the burden on clinical 
load, and lengthy approval processes. Strengths include the 
high burden of disease and the prevalence of treatment-
naïve patients. Participants expressed a significant need for 
a national initiative to support and enhance the conduct of 
public sector RCTs. Research methods training and statistical 
support were viewed as key. There was a broad range of 
views regarding the structure and focus of such an initiative, 
but there was agreement that the national government should 
provide specific funding for this purpose.
Conclusions. Stakeholders generally support the establishment 
of a national clinical trials support initiative. Consideration 
must be given to the sustainability of such an initiative, in 
terms of funding, staffing, expected research outputs and 
permanence of location.
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(‘snow-balling’). The number of interviews was considered 
sufficient when participants from at least one of all the key 
institutions had been interviewed and no new information was 
forthcoming. We anticipated that a minimum of 20 interviews 
would be required to ensure inclusion of all universities, 
government organisations and non-government organisations 
active in the conduct, use or funding of trials.
Data collection and management
The study received ethics approval from the MRC Ethics 
Committee in February 2008. The principal investigator (NS) 
conducted the interviews between May and August 2008. 
Interviews were semi-structured and open-ended, made use 
of probes to explore key areas, and took approximately 45 
minutes each. Participants were encouraged to base their 
answers on experience in their representative institutions 
and on their personal knowledge of the South African 
clinical trials landscape. They were audio-recorded with the 
interviewee’s permission after signing an informed consent 
form. An individual unaware of the identity of the interviewee 
transcribed the interviews. Transcripts and identifying material 
were accessible only to the principal investigator.
Data analysis
The transcripts of the in-depth interviews were reviewed, 
and a code list of the emergent themes and sub-themes 
was generated for analysis. Participants were emailed the 
preliminary analysis for additional comment. The data are 
presented as frequencies, and illustrative quotations appear in 
italics.
Results
Characteristics of key informants
Sixteen interviews (15 face-to-face and 1 telephonic) were 
conducted; 14 were conducted with a single informant, 1 was 
conducted with 2 informants, and 1 with 3 informants. The 
views of 19 senior individuals from 14 institutions were thus 
elicited. At 7 of the 8 South African universities with clinical 
faculties of health sciences, interviews were conducted at 
the level of a dean or equivalent. The representatives from 
other institutions were all at senior management levels. Two 
key informants who agreed to be interviewed subsequently 
were not able to participate in the interview. The Medicines 
Control Council (MCC) was invited to participate, but no 
representative was forthcoming.
Institutional trial experience
Of the 10 institutions which reported conducting clinical trials, 
9 believed that they were experienced in trial conduct, with 2 
reporting that the level of trial experience was variable across 
the institution. At the time of the interview, 3 institutions were 
conducting over 50 trials, 3 were conducting between 10 and 50 
trials, and 4 were conducting less than 10 trials. Respondents 
whose institutions did not conduct trials reported using trial 
results to determine policies or were involved in administering 
trial research training, or funding.
Trial funding
All informants reported funding sources as broad-based, 
including a combination of institutional support and grants, 
international agencies, the MRC and pharmaceutical industry. 
Strong themes that emerged were: (i) lack of funding for 
investigator-driven (also known as self-initiated) trials; and (ii) 
difficulty in obtaining funding for specific research questions 
important to the public sector.
Strengths of and challenges to trial conduct
Participants identified the high disease prevalence and 
relatively strong infrastructure in the South African health 
system as being fundamental to potentially successful trial 
conduct in the country. Participants identified the lengthy MCC 
processes and complex logistics of RCTs, the high cost of trials 
and the potential burden of trial conduct on clinical care as 
major obstacles.
Training and support needs
Table I outlines the identified training and support needs, 
with research methods training a strong theme. Responses to 
needs for support structures were more diverse, with assistance 
with statistical analysis, data management and science writing 
emerging across the responses.
Participants were specifically asked if they believed 
that South Africa had sufficient and suitably experienced 
researchers able to conduct monitoring and quality control of 
RCTs. Of the 13 who expressed an opinion, 3 believed this to 
be true, 5 felt there were some suitably skilled researchers but 
insufficient for the need, and 5 stated that this was a major 
skills shortcoming.
Need for a clinical trials support unit
In 15 of 16 interviews, participants reported a need for an 
initiative at national level to encourage and improve the 
conduct of clinical trials. One interviewee stated that it should 
be focused on previously disadvantaged institutions; one 
stated that it should start small, and another stated that it 
should focus only on quality control and monitoring. Several 
participants expressed surprise that such an entity did not exist 
already.
Participants were asked to consider how such an entity 
would best operate and where its funding should come from. 
Four potential operational structures (Table II) and 4 key 
deliverables were identified: (i) provision of quality control, 
monitoring, and oversight of trials; (ii) training pertaining 
specifically to trials to avoid duplication with current 
university-based training programmes; (iii) mentoring support 
for the entire trial process from grant procurement to final 
report writing; and (iv) potential to play an advocacy role to 
streamline regulatory processes.
In 15 of the 16 interviews, representatives suggested that 
funding be derived from a national government source; specific 
recommendations included the MRC (5), DoH (2), Department 
of Education (1), Department of Science and Technology 
(1), national or provincial government with no departments 
specified (3), a combination of national departmental funding 
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(3), and the pharmaceutical industry in partnership with the 
DoH (1). One respondent recommended that trial sponsors 
including international agencies should contribute funds for 
establishing such an entity.
Many participants appeared dispirited by the apparent lack 
of long-term sustainability of such an initiative, some citing 
previous failed attempts at national collaborative projects, and 
cautioning about the potential for competition rather than 
collaboration between institutions.
Discussion
South African clinical trial research community senior 
stakeholders and decision-makers voiced the significant need 
for a national clinical trials initiative to support and enhance 
the conduct of public sector RCTs. Participants agreed that, 
ideally, the national government should provide specific 
funding to establish this initiative, and that its long-term 
sustainability should be carefully considered.
Kahn and Gastrow estimate that industry turnover in clinical 
trials run by the South African pharmaceutical industry is 
worth around R14.1 billion annually.9 Despite this, they argue 
that South Africa neither has the requisite human resources 
to be competitive internationally, nor does it invest enough. 
They report that increased trial activity could be attracted to 
South Africa by our well-established credentials in medical 
research, the high burden of disease and relatively drug-naïve 
populations. These factors were recognised by our participants 
as key reasons for conducting trials locally. Recommendations 
for a more proactive regulatory environment were echoed in 
our respondents’ complaints regarding MCC waiting times and 
requests for assistance in negotiating the regulatory processes.
Most participants described the difficult local conditions 
facing trial investigators. Conducting trials within communities 
where literacy and health care knowledge of participants 
and providers is poor, has led to speculation that trials of 
high methodological quality are not possible within these 
settings.10-12 A comparison of African and North American 
HIV/AIDS RCTs found that the reported methodological 
quality of African trials was better than that of North American 
trials, independent of the country of residence of the principal 
investigator,13 which is encouraging for the future of local trial 
conduct.
Qualitative research was appropriate as it helps the 
development of concepts, giving emphasis to the meanings, 
experiences and views of all participants.14 Individual 
interviews allowed detailed exploration of the issues15 and 
provided rich, comprehensive data16 which might not have 
been achieved with a survey-driven approach. Consistency was 
ensured by each interview being conducted by NS. Interviews 
took place over a 4-month period to maximise availability of 
the appropriate institutional key informants. All but one of the 
pre-specified institutions were represented in the final sample.
Table I. Training and support needs identified by participants
Training needs      Support needs
•   Good clinical practice     •   Statistical analysis and management
•   Research methods: general and specific to trials  •   Quality control and monitoring
•   Statistics      •   Data collection
•   Epidemiology      •   Scientific writing
•   Data management     •   Ethics application and approval
•   Project management     •   Negotiating the regulatory environment
•   Protocol and grant writing     •   Mentorship
•   On-site training of field staff    •   Database management
•   Ethics training      •   Pilot testing
•   Oversight training     •   Guidance in using tax incentives (relevant to industry-led trials)
       •   Project management
       •   Funding procurement
       •   A forum for encouraging debate
Table II. Proposed models of a national clinical trials support initiative
Model    Structure
Hub-and-spokes    Unit is fully staffed and situated at a national centre, such as the MRC, and provides support and 
training on an ad hoc basis to academic institutions, non-government organisations and research 
councils conducting RCTs
Collaborative    Groups and individuals within academic departments work together in a consortium 
Administration and management of the collaboration is in a central site, either in one of the 
academic institutions or at a national centre
Virtual     Groups, individuals within academic departments, and those based at research councils work 
together in a consortium, but no central site exists 
     Communication is done electronically 
     A website is administered with training tools and on-line support divided according to the 
strengths of the member groups 
    Administration and supervision is done by one of the academic departments
Extramural unit within university  No central site exists; any available national funding is directly allocated to a university 
department to establish an internal trials unit
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Limitations
The study is subject to limitations inherent in qualitative 
research.15 It was funded and conducted by the MRC, which 
has an interest in the location of such a unit, which might 
have influenced the investigators’ interpretation of results. 
Participants working in government departments may be far 
removed from the ‘coalface’, and their comments may not 
accurately reflect needs. However, given the consistency of 
comments from all participants, this does not seem to have 
been a major limiting factor. Perhaps most limiting were the 
voices missing from this study, notably a stakeholder from the 
MCC. Feasibility issues prohibited a larger study, but opinions 
of more clinical investigators and of trial participants, civil 
society groups and community representatives would have 
enriched the study. Such studies could be key outputs of a 
future clinical trials unit. 
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